OBI-221 / OBI Pharma - LARVOL DELTA

The MET/HER3 antibody-drug conjugate with dual payload: A dual-target approach to eliminate tumor escape mechanism (AACR 2026) - "Broad activity was observed in c-MET/HER3 dual-positive non-small cell lung cancer and colorectal cancer models. This glycan-based site specific MET/HER3 bispecific dual-payload ADC warrants further clinical investigation as a promising therapeutic option for refractory tumors co-expressing cMET and HER3."

ADC • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ERBB3 • MET